Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Jun;22(11):3875-91.
doi: 10.1128/MCB.22.11.3875-3891.2002.

Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts

Maria I Kontaridis  1 , Xiangdong Liu, Lei Zhang, Anton M Bennett
Affiliations

Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts

Maria I Kontaridis et al. Mol Cell Biol. 2002 Jun.

Abstract

Ligand activation of the fibroblast growth factor receptor (FGFR) represses myogenesis and promotes activation of extracellular signal-regulated kinases 1 and 2 (Erks). The precise mechanism through which the FGFR transmits both of these signals in myoblasts remains unclear. The SH2 domain-containing protein tyrosine phosphatase, SHP-2, has been shown to participate in the regulation of FGFR signaling. However, no role for SHP-2 in FGFR myogenic signaling is known. In this study, we show that stimulation of C2C12 myoblasts with FGF-2 induces SHP-2 complex formation with tyrosyl-phosphorylated FGFR substrate 2 alpha (FRS-2 alpha). Both the catalytic activity and, to a much lesser extent, the Grb2 binding-tyrosyl phosphorylation sites of SHP-2 are required for maximal FGF-2-induced Erk activity and Elk-1 transactivation. When overexpressed in C2C12 myoblasts, wild-type SHP-2, but not a catalytically inactive SHP-2 mutant, potentiates the suppressive effects of FGF-2 on muscle-specific gene expression. In addition, expression of a constitutively active mutant of SHP-2 is sufficient to prevent myogenesis. The constitutively active mutant of SHP-2 induces hyper-tyrosyl phosphorylation of FRS-2 alpha but fails to stimulate or potentiate either FGF-2-induced Erk activation or Elk-1 transactivation. These data suggest that in myoblasts, SHP-2 represses myogenesis via a pathway that is independent of the Erks. We propose that SHP-2 plays a pivotal role in FGFR signaling in myoblasts via both Erk-dependent and Erk-independent pathways.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
FGF-2 induces FRS-2α tyrosyl phosphorylation and complex formation with SHP-2 in C2C12 myoblasts. (A) C2C12 myoblasts were serum starved overnight and then either left untreated (−) or treated (+) with FGF-2 (10 ng/ml) for 10 min. Lysates from unstimulated and stimulated myoblasts were immunoprecipitated either with NRS or with anti-SHP-2 antibodies. Immune complexes and total-cell lysates (TCL) from unstimulated and FGF-2-stimulated C2C12 myoblasts were resolved by SDS-8% PAGE and analyzed by immunoblotting with antiphosphotyrosine (4G10) antibodies (pTyr). The lower panel represents a reprobe of the membrane with anti-SHP-2 antibodies. (B) Lysates prepared from either unstimulated (−) or FGF-2-stimulated (+) C2C12 myoblasts were prepared as described above. Lysates were subjected either to affinity precipitation with p13-Suc-1 agarose beads (Suc1) or to immunoprecipitation with anti-SHP-2 antibodies. p13-Suc-1 agarose affinity complexes or anti-SHP-2 antibody immune complexes were resolved by SDS-PAGE, and tyrosyl-phosphorylated proteins were visualized by immunoblotting with 4G10 antibodies. (C) Lysates prepared as described in the legend to panel B were subjected to immunoprecipitation (IP) either with NRS or with anti-FRS-2α antibodies (1st IP). The supernatants from the first IP were either left alone or subsequently immunoprecipitated with anti-SHP-2 antibodies or anti-FRS-2α antibodies (2nd IP). Immune complexes were analyzed by immunoblotting with 4G10 antibodies. (D) Lysates were prepared from C2C12 myoblasts that were either left untreated (−) or treated (+) with FGF-2 (10 ng/ml) for 10 min. Lysates were immunoprecipitated either with NRS or with anti-FRS-2α antibodies, and immune complexes were resolved and immunoblotted with anti-SHP-2 antibodies. The lower panel represents a reprobe of the membrane with anti-FRS-2α antibodies.
FIG. 1.
FIG. 1.
FGF-2 induces FRS-2α tyrosyl phosphorylation and complex formation with SHP-2 in C2C12 myoblasts. (A) C2C12 myoblasts were serum starved overnight and then either left untreated (−) or treated (+) with FGF-2 (10 ng/ml) for 10 min. Lysates from unstimulated and stimulated myoblasts were immunoprecipitated either with NRS or with anti-SHP-2 antibodies. Immune complexes and total-cell lysates (TCL) from unstimulated and FGF-2-stimulated C2C12 myoblasts were resolved by SDS-8% PAGE and analyzed by immunoblotting with antiphosphotyrosine (4G10) antibodies (pTyr). The lower panel represents a reprobe of the membrane with anti-SHP-2 antibodies. (B) Lysates prepared from either unstimulated (−) or FGF-2-stimulated (+) C2C12 myoblasts were prepared as described above. Lysates were subjected either to affinity precipitation with p13-Suc-1 agarose beads (Suc1) or to immunoprecipitation with anti-SHP-2 antibodies. p13-Suc-1 agarose affinity complexes or anti-SHP-2 antibody immune complexes were resolved by SDS-PAGE, and tyrosyl-phosphorylated proteins were visualized by immunoblotting with 4G10 antibodies. (C) Lysates prepared as described in the legend to panel B were subjected to immunoprecipitation (IP) either with NRS or with anti-FRS-2α antibodies (1st IP). The supernatants from the first IP were either left alone or subsequently immunoprecipitated with anti-SHP-2 antibodies or anti-FRS-2α antibodies (2nd IP). Immune complexes were analyzed by immunoblotting with 4G10 antibodies. (D) Lysates were prepared from C2C12 myoblasts that were either left untreated (−) or treated (+) with FGF-2 (10 ng/ml) for 10 min. Lysates were immunoprecipitated either with NRS or with anti-FRS-2α antibodies, and immune complexes were resolved and immunoblotted with anti-SHP-2 antibodies. The lower panel represents a reprobe of the membrane with anti-FRS-2α antibodies.
FIG. 2.
FIG. 2.
FGF-2 induces tyrosyl phosphorylation of FRS-2α but not IRS-1 in C2C12 myoblasts. C2C12 myoblasts were serum deprived for 18 h and then either left unstimulated (−) or stimulated (+) with either FGF-2 (10 ng/ml), insulin (100 nM), or IGF-I (100 ng/ml) for 10 min. These cell lysates were immunoprecipitated (IP) with either anti-FRS-2α or anti-IRS-1 antibodies; immune complexes were resolved by SDS-PAGE and immunoblotted by using 4G10 antiphosphotyrosine antibodies. The same membranes were then reprobed with either anti-FRS-2α or anti-IRS-1 antibodies.
FIG. 3.
FIG. 3.
SHP-2's catalytic activity is required for FGF-2-mediated activation of Elk-1 and Erk2 in C2C12 myoblasts. (A) C2C12 myoblasts were transfected with 0.5 μg of 5XGAL4-luciferase, 0.5 μg of Elkc-GAL4, 0.5 μg of β-galactosidase, and 2.5 μg of either vector alone, WT SHP-2, the catalytically inactive cysteine-to-serine (CS) mutant of SHP-2, or the Y542F/Y580F (Y2F) double tyrosyl phosphorylation site mutant of SHP-2. Twenty-four hours after transfection, myoblasts were transferred to serum deprivation medium for a further 24 h and were either left unstimulated (−) or stimulated (+) with FGF-2 (10 ng/ml) for 4 h. Luciferase and β-galactosidase activity assays were performed as described in Materials and Methods, and the raw luciferase values were normalized to β-galactosidase activity. Transfections were performed in triplicate for each condition, and the normalized (relative to the unstimulated vector control) data are means ± standard errors of the means from at least three separate experiments. Immunoblotting of C2C12 myoblasts with anti-Myc antibodies confirmed similar expression levels of transfected SHP-2 (data not shown). (B) C2C12 myoblasts were transfected with 2 μg of HA-Erk2 and 10 μg of either vector alone, WT SHP-2, or the CS or Y2F mutant of SHP-2 into serum deprivation medium. Twenty-four hours after transfection, the cells were either left unstimulated or stimulated with FGF-2 (10 ng/ml) for 10, 30, or 60 min. Myoblasts were then harvested, and HA-tagged Erk2 was immunoprecipitated (IP) with anti-HA antibodies. These HA-Erk2 immune complexes were assayed for Erk2 activity by using MBP as a substrate. Lower panels show results of representative control experiments with the above lysates in which the HA-Erk2 immune complexes were resolved by SDS-PAGE and immunoblotted with anti-Erk2 antibodies, and the cell lysates were examined for SHP-2 expression levels by immunoblotting.
FIG. 4.
FIG. 4.
SHP-2 potentiates the inhibition of FGF-2 on myogenic gene expression. (A) C2C12 myoblasts were cultured either in the presence of serum (10% FBS) or in the presence of FGF-2 (10 ng/ml), and SHP-2 was immunoprecipitated (IP) as described in the text. Anti-SHP-2 immune complexes were resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine (4G10) antibodies (pTyr). The lower panel represents a reprobe of this membrane with anti-SHP-2 antibodies. (B) C2C12 myoblasts cultured in the presence of either serum or FGF-2 were transfected with 0.5 μg of MCK-luciferase (MCK-Luc), 0.5 μg of β-galactosidase, and 2.5 μg of either the pJ3 vector control, WT SHP-2, or the CS mutant of SHP-2. Twenty-four hours after transfection, lysates were prepared for analysis of MCK-luciferase and β-galactosidase activities. Transfections were performed in triplicate and normalized to the vector control. Results are means ± standard errors of the means from three separate experiments, and data were analyzed by using a one-tailed paired t test. ∗, P = 0.01 for WT SHP-2 in serum versus WT SHP-2 in FGF-2; ∗∗, P = 0.03 for WT SHP-2 in serum versus the SHP-2 CS mutant in serum; ∗∗∗, P = 0.03 for WT SHP-2 in FGF-2 versus the SHP-2 CS mutant in FGF-2.
FIG. 5.
FIG. 5.
Constitutive activation and association of SHP-2 E76A with FRS-2α and p120 tyrosyl-phosphorylated proteins in C2C12 myoblasts. (A) Schematic representation of the adenovirus construct expressing GFP and the constitutively active mutant of SHP-2 in which E76 within theN-SH2 domain was mutated to A76. (B) C2C12 myoblasts were either left uninfected or infected with either pAd-GFP or pAd-GFP-SHP-2-E76A (pAd-E76A) for 24 h. Representative photomicrographs (magnification, ×100) are phase-contrast images (left) and corresponding indirect-immunofluorescence images (right) and show ∼100% of the adenovirus-infected myoblasts expressing GFP. (C) C2C12 myoblasts were either left uninfected or infected with pAd-GFP or pAd-E76A for 24 h. Myoblasts were then serum starved for an additional 18 h and either left unstimulated or restimulated with FGF-2 (10 ng/ml) for 10 min. Lysates from these C2C12 myoblasts were subjected to immunoprecipitation (IP) with either anti-SHP-2 antibodies (for uninfected myoblasts) or anti-Myc (9E10) antibodies (for infected myoblasts). These immune complexes were resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine (pTyr) antibodies. The lower panel represents a reprobe of the membrane with anti-SHP-2 antibodies. (D) 293 cells were left untransduced or were transduced with pAd-GFP, pAd-WT, or pAd-E76A for 24 h. SHP-2 was immunoprecipitated with anti-Myc antibodies, and immune complexes were used to perform a phosphatase assay using pNPP as a substrate. Results shown are representative of two independent experiments, where SHP-2 E76A gives an ∼25-fold-higher level of pNPP hydrolysis than WT SHP-2. The inset shows that equivalent levels of SHP-2 protein were expressed in these immune complex phosphatase assays.
FIG. 5.
FIG. 5.
Constitutive activation and association of SHP-2 E76A with FRS-2α and p120 tyrosyl-phosphorylated proteins in C2C12 myoblasts. (A) Schematic representation of the adenovirus construct expressing GFP and the constitutively active mutant of SHP-2 in which E76 within theN-SH2 domain was mutated to A76. (B) C2C12 myoblasts were either left uninfected or infected with either pAd-GFP or pAd-GFP-SHP-2-E76A (pAd-E76A) for 24 h. Representative photomicrographs (magnification, ×100) are phase-contrast images (left) and corresponding indirect-immunofluorescence images (right) and show ∼100% of the adenovirus-infected myoblasts expressing GFP. (C) C2C12 myoblasts were either left uninfected or infected with pAd-GFP or pAd-E76A for 24 h. Myoblasts were then serum starved for an additional 18 h and either left unstimulated or restimulated with FGF-2 (10 ng/ml) for 10 min. Lysates from these C2C12 myoblasts were subjected to immunoprecipitation (IP) with either anti-SHP-2 antibodies (for uninfected myoblasts) or anti-Myc (9E10) antibodies (for infected myoblasts). These immune complexes were resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine (pTyr) antibodies. The lower panel represents a reprobe of the membrane with anti-SHP-2 antibodies. (D) 293 cells were left untransduced or were transduced with pAd-GFP, pAd-WT, or pAd-E76A for 24 h. SHP-2 was immunoprecipitated with anti-Myc antibodies, and immune complexes were used to perform a phosphatase assay using pNPP as a substrate. Results shown are representative of two independent experiments, where SHP-2 E76A gives an ∼25-fold-higher level of pNPP hydrolysis than WT SHP-2. The inset shows that equivalent levels of SHP-2 protein were expressed in these immune complex phosphatase assays.
FIG. 6.
FIG. 6.
A constitutively active mutant of SHP-2 fails to either activate or potentiate FGF-2-induced Erk. (A) C2C12 myoblasts that were left uninfected or infected with pAd-GFP, pAd-WT, or pAd-E76A were serum starved and either left untreated (−) or treated (+) with FGF-2 (10 ng/ml) for the indicated lengths of time. Activation of the Erks was assessed by immunoblotting of lysates prepared from the indicated conditions with anti-phospho-Erk antibodies (pErk). Immunoblots were reprobed for Erk and SHP-2 expression levels. Arrows to the right indicate the positions of Erk1 and Erk2. The graph shows results of densitometric analysis of pErk1/2 levels from experiments performed as described above. Normalized pErk1/2 represents the ratio of the densitometric units of pErk1/2 to the corresponding densitometric units of Erk1/2. Data shown are means ± standard errors of the means from four to five independent experiments. (B) C2C12 myoblasts either were left uninfected or were infected with pAd-GFP, pAd-WT, or pAd-E76A. Twenty-four hours after infection, the cells were serum starved for an additional 24 h and then were either left unstimulated or restimulated with FGF-2 (10 ng/ml) for 10 min. Myoblasts were then harvested, and lysates were immunoprecipitated (IP) with anti-Erk2 antibodies. These immune complexes were assayed for Erk2 activity by using MBP as a substrate. Lower panels show results of representative control experiments from the same lysates in which the Erk2 immune complexes were resolved by SDS-PAGE and immunoblotted with anti-Erk2 antibodies, and cell lysates were examined for SHP-2 expression levels by immunoblotting.
FIG. 7.
FIG. 7.
Effect of the constitutively active SHP-2 mutant on Elk-1 transactivation. (A) Myc-tagged WT SHP-2 and SHP-2 E76A were subcloned into the pIRES-GFP vector and were transfected, along with the pIRES-GFP control, into 293 cells. Anti-Myc-SHP-2 immune complexes were measured for phosphatase activity as described in Materials and Methods. Results shown are representative of two independent experiments, where E76A gives an ∼15-fold-higher level of pNPP hydrolysis than WT SHP-2. (Inset) Levels of SHP-2 protein assayed for phosphatase activity in these immune complexes were determined by immunoblotting of the resolved immune complexes with anti-SHP-2 antibodies. (B) C2C12 myoblasts were transfected with either pIRES-GFP, WT SHP-2 (pIRES-WT), or the constitutively active mutant of SHP-2 (pIRES-E76A). As a positive control, activated Ras [Ras61(Leu)] was also transfected into C2C12 myoblasts. After 24 h, the cultures were transferred to serum-free medium for a further 24 h, after which Elk-1 luciferase and β-galactosidase activities were determined. The experiments were performed in triplicate, and results are means ± standard errors of the means from three separate experiments, with Elk-1 luciferase activity normalized to β-galactosidase activity. (Inset) Equivalent expression levels of WT SHP-2 and SHP-2 E76A were confirmed following transfection of C2C12 myoblasts with pIRES-GFP, pIRES-WT, or pIRES-E76A. Transfectants were cultured for 48 h, and lysates were prepared and immunoprecipitated with anti-Myc (9E10) antibodies. IP, immunoprecipitation.
FIG. 8.
FIG. 8.
The constitutively active mutant of SHP-2 is sufficient to block myogenesis. C2C12 myoblasts were infected either with pAd-GFP (A), pAd-WT (B), or pAd-E76A (C) 24 h prior to the initiation of differentiation or with pAd-E76A 24 h postdifferentiation (D). Shown are representative photomicrographs of Wright-Giemsa-stained C2C12 myoblasts (top row) and coimmunofluorescence images of adenovirus-infected myoblasts expressing GFP that were stained with Texas red phalloidin (bottom row). Infection of C2C12 myoblasts with the pAd-E76A adenovirus 24 h prior to the initiation of differentiation prevents multinucleated myotube formation as compared to pAd-GFP- or pAd-WT-infected myoblasts. When C2C12 myoblasts are infected with pAd-E76A 24 h after the initiation of differentiation, multinucleated myotube formation proceeds normally.
FIG. 9.
FIG. 9.
The constitutively active mutant of SHP-2 is sufficient to block muscle-specific gene expression. Lysates were prepared from C2C12 myoblasts that were either uninfected or infected 24 h prior to (A) or 24 h after (B) differentiation with pAd-GFP, pAd-WT, or pAd-E76A. Lysates were immunoblotted for the expression of SHP-2 and MHC. (C) Densitometric analysis of MHC expression in C2C12 myoblasts infected with either pAd-GFP, pAd-WT, or pAd-E76A 24 h prior to or 24 h following the initiation of differentiation. Data are means ± standard errors of the means from four to six separate experiments.
FIG. 10.
FIG. 10.
The activated mutant of SHP-2 induces hyper- and sustained tyrosyl phosphorylation of FRS-2α. C2C12 myoblasts were infected with pAd-GFP, pAd-E76A, or pAd-WT for 24 h prior to serum deprivation. Twenty-four hours later, the cells were stimulated with 10 ng of FGF-2/ml for the indicated times. (A) Cells were harvested, and lysates were subjected to affinity precipitation with p13-Suc-1 agarose beads. This complex was resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine (4G10) antibodies (pTyr) or anti-FRS-2α antibodies for the reprobe. The graph shows the results of densitometric analysis of the above experiment represented as arbitrary phosphotyrosyl FRS-2α levels normalized to total FRS-2α levels. (B) C2C12 myoblasts were infected with either pAd-GFP, pAd-E76A, or pAd-WT for 24 h prior to serum deprivation. Twenty-four hours later, the cells were stimulated with 10 ng of FGF-2/ml for 10 min. Cells were harvested, and lysates were subjected to immunoprecipitation with anti-FGFR antibodies, resolved by SDS-PAGE, and immunoblotted with anti-pTyr (4G10) antibodies. IP, immunoprecipitation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adachi, M., M. Sekiya, T. Miyachi, K. Matsuno, Y. Hinoda, K. Imai, and A. Yachi. 1992. Molecular cloning of a novel protein-tyrosine phosphatase, SH-PTP3, with sequence similarity to the src-homology region 2. FEBS Lett. 314:335-339. - PubMed
    1. Ahmad, S., D. Banville, Z. Zhao, E. H. Fischer, and S.-H. Shen. 1993. A widely expressed human protein tyrosine phosphatase contains src homology 2 domains. Proc. Natl. Acad. Sci. USA 90:2197-2201. - PMC - PubMed
    1. Bennett, A. M., S. F. Hausdorff, A. M. O'Reilly, R. M. Freeman, and B. G. Neel. 1996. Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol. Cell. Biol. 16:1189-1202. - PMC - PubMed
    1. Bennett, A. M., T. L. Tang, S. Sugimoto, C. T. Walsh, and B. G. Neel. 1994. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor β to Ras. Proc. Natl. Acad. Sci. USA 91:7335-7339. - PMC - PubMed
    1. Bennett, A. M., and N. K. Tonks. 1997. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 278:1288-1291. - PubMed

Publication types

MeSH terms

Substances